First FDA Cleared Ophthalmic App for Monitoring AMD and DR
“Our clinical trials have confirmed that the results from this convenient home test correlate well with in-office physician assessment and can potentially improve clinical outcomes by bringing in patients for earlier-than-planned examination and possibly treatment”
Age related macular degeneration is the leading cause of blindness for people over 60, and diabetic retinopathy vision loss continues to grow with the increasing prevalence of diabetes. The new mVT™ Service is the only simple, low cost, mobile, validated method available for these patients to test their vision at home. Patients take a simple 4-6 minute self-test, performed on the timetable recommended by the doctor (usually twice a week). The patient’s confidential results are automatically delivered to the Physician Portal for review and analysis.
The mVT™ Service utilizes proven patented proprietary algorithms to assess visual function and detect changes between physician visits. A significant change in the eye condition sends an alert to the doctor who will determine if an earlier intervention is required, such as new appointment, assessment or treatment.
The mVT™ Service, which includes the App and the Physician’s Portal, is available by prescription only and costs patients $8.95/month…..
Read more: http://www.businesswire.com/news/home/20150427005025/en/FDA-Cleared-Ophthalmic-App-Monitoring-AMD-DR#.VT983SFVhBc
Source: Business Wire